马锐利,张 帆

肠易激综合征（Irritable Bowel Syndrome，IBS）是一种常见的功能性胃肠病，临床表现为反复发作的腹痛、腹胀及排便习惯改变，但缺乏明确的器质性病变基础。传统观点认为IBS是一种单纯的“功能紊乱”而无器质性改变，在过去的几年中，胃肠道内的免疫学改变和低度炎症以及异常的神经免疫相互作用在IBS的病理生理学中起着重要作用。近年来越来越多的证据表明，IBS可能是机体对内外环境威胁的一系列复杂防御反应，本文将从防御反应的角度重新审视IBS的发病机制及临床表现。

肠易激综合征；防御反应；发病机制；临床表现

[1] Read NW.Irritable bowel syndrome(IBS)--definition and pathophysiology.Scand J Gastroenterol Suppl.1987;130:7-13. [2] Drossman DA.Functional Gastrointestinal Disorders:History,Pathophysiology,Clinical Features and Rome IV.Gastroenterology. Published online February 19,2016. [3] Oka P,Parr H,Barberio B,Black CJ,Savarino EV,Ford AC.Global prevalence of irritable bowel syndrome according to Rome III or IV criteria:a systematic review and meta-analysis[published correction appears in Lancet Gastroenterol Hepatol.2020 Dec;5(12):e8. [4] Lovell RM,Ford AC.Global prevalence of and risk factors for irritable bowel syndrome:a meta-analysis.Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4. [5] Vanuytsel T,Bercik P,Boeckxstaens G.Understanding neuroimmune interactions in disorders of gut-brain interaction:from functional to immune-mediated disorders.Gut.2023;72(4):787-798. [6] Öhman L,Törnblom H,Simrén M.Crosstalk at the mucosal border:importance of the gut microenvironment in IBS.Nat Rev Gastroenterol Hepatol.2015;12(1):36-49. [7] Ohman L,Simrén M.Pathogenesis of IBS:role of inflammation,immunity and neuroimmune interactions.Nat Rev Gastroenterol Hepatol. 2010;7(3):163-173. [8] Furness JB.The enteric nervous system and neurogastroenterology.Nat Rev Gastroenterol Hepatol.2012;9(5):286-294.Published 2012 Mar 6. [9] Schneider KM,Blank N,Alvarez Y,et al.The enteric nervous system relays psychological stress to intestinal inflammation.Cell.2023; 186(13):2823-2838.e20. [10] Spiller R,Major G.IBS and IBD-separate entities or on a spectrum?.Nat Rev Gastroenterol Hepatol.2016;13(10):613-621. [11] Christensen J,Schedl HP,Clifton JA.The small intestinal basic electrical rhythm(slow wave)frequency gradient in normal men and in patients with variety of diseases.Gastroenterology.1966;50(3):309-315 [12] Zhou Q,Verne GN.New insights into visceral hypersensitivity--clinical implications in IBS.Nat Rev Gastroenterol Hepatol.2011; 8(6):349-355. [13] Lu Y,Chai Y,Qiu J,et al.Integrated omics analysis reveals the epigenetic mechanism of visceral hypersensitivity in IBS-D.Front Pharmacol.2023;14:1062630.Published 2023 Mar 16. [14] Zhang R,Zou N,Li J,et al.Elevated expression of c-fos in central nervous system correlates with visceral hypersensitivity in irritable bowel syndrome(IBS):a new target for IBS treatment.Int J Colorectal Dis.2011;26(8):1035-1044. [15] Azpiroz F,Bouin M,Camilleri M,et al.Mechanisms of hypersensitivity in IBS and functional disorders.Neurogastroenterol Motil. 2007;19(1 Suppl):62-88. [16] Piche T.Tight junctions and IBS--the link between epithelial permeability,low-grade inflammation,and symptom generation?. Neurogastroenterol Motil.2014;26(3):296-302. [17] Liu S,Huang Q,Huang Q,et al.The protective effects of electroacupuncture on intestinal barrier lesions in IBS and UC model.Sci Rep.2023;13(1):7276.Published 2023 May 4. [18] Awad K,Barmeyer C,Bojarski C,et al.Epithelial Barrier Dysfunction in Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)via Downregulation of Claudin-1.Cells.2023;12(24):2846.Published 2023 Dec 15. [19] Franks I.IBS:New insights into pathogenesis of diarrhea-predominant IBS.Nat Rev Gastroenterol Hepatol.2012;9(5):245.Published 2012 Apr 3. [20] Ohman L,Simrén M.Pathogenesis of IBS:role of inflammation,immunity and neuroimmune interactions.Nat Rev Gastroenterol Hepatol.2010;7(3):163-173. [21] Krystel-Whittemore M,Dileepan KN,Wood JG.Mast Cell:A Multi-Functional Master Cell.Front Immunol.2016;6:620.Published 2016 Jan 6. [22] Chang L,Adeyemo M,Karagiannides I,et al.Serum and colonic mucosal immune markers in irritable bowel syndrome[published correction appears in Am J Gastroenterol.2012 Mar;107(3):492.Karagiannidis,Iordanis[corrected to Karagiannides,Iordanis]].Am J Gastroenterol.2012;107(2):262-272. [23] Mearin F,Lacy BE,Chang L,et al.Bowel Disorders.Gastroenterology.Published online February 18,2016. [24] Fichna J,Storr MA.Brain-Gut Interactions in IBS.Front Pharmacol.2012;3:127.Published 2012 Jul 5. [25] Zou N,Lv H,Li J,et al.Changes in brain G proteins and colonic sympathetic neural signaling in chronic-acute combined stress rat model of irritable bowel syndrome(IBS)[published correction appears in Transl Res.2009 Mar;153(3):142].Transl Res.2008;152(6):283-289. [26] Dinan TG,Cryan J,Shanahan F,Keeling PW,Quigley EM.IBS:An epigenetic perspective.Nat Rev Gastroenterol Hepatol.2010;7(8):465-471. [27] Császár-Nagy N,Bókkon I.Hypnotherapy and IBS:Implicit,long-term stress memory in the ENS?.Heliyon.2022;9(1):e12751.Published 2022 Dec 30. [28] Noemi CN,Bob P,Bókkon I.Long-Term Implicit Epigenetic Stress Information in the Enteric Nervous System and its Contribution to Developing and Perpetuating IBS.Curr Neuropharmacol.2024;22(13):2100-2112. [29] Huang KY,Hu JY,Lv M,et al.Cerebral cortex changes in FD,IBS,and GERD:A Mendelian randomization study.J Affect Disord.2025; 369:1153-1160. [30] Labus JS,Delgadillo DR,Cole S,et al.IBS stress reactivity phenotype is associated with blood transcriptome profiles and microstructural and functional brain changes.Preprint.medRxiv.2024;2024.08.07.24311369.Published 2024 Aug 8. [31] Simrén M.IBS with intestinal microbial dysbiosis:a new and clinically relevant subgroup?.Gut.2014;63(11):1685-1686. [32] Gasbarrini A,Lauritano EC,Garcovich M,Sparano L,Gasbarrini G.New insights into the pathophysiology of IBS:intestinal microflora, gas production and gut motility.Eur Rev Med Pharmacol Sci.2008;12 Suppl 1:111-117 [33] Collins SM.A role for the gut microbiota in IBS.Nat Rev Gastroenterol Hepatol.2014;11(8):497-505. [34] Sciavilla P,Strati F,Di Paola M,et al.Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients.Appl Microbiol Biotechnol.2021;105(8):3277-3288. [35] Casén C,VebøHC,Sekelja M,et al.Deviations in human gut microbiota:a novel diagnostic test for determining dysbiosis in patients with IBS or IBD.Aliment Pharmacol Ther.2015;42(1):71-83. [36] Zheng H,Chen Y,Lu S,et al.Mechanosensory Piezo2 regulated by gut microbiota participates in the development of visceral hypersensitivity and intestinal dysmotility.Gut Microbes.2025;17(1):2497399. [37] Petitfils C,Maurel S,Payros G,et al.Identification of bacterial lipopeptides as key players in IBS.Gut.2023;72(5):939-950. [38] Russo F,Chimienti G,Riezzo G,et al.Adipose Tissue-Derived Biomarkers of Intestinal Barrier Functions for the Characterization of Diarrhoea-Predominant IBS.Dis Markers.2018;2018:1827937.Published 2018 Nov 28. [39] Vanuytsel T,Bercik P,Boeckxstaens G.Understanding neuroimmune interactions in disorders of gut-brain interaction:from functional to immune-mediated disorders.Gut.2023;72(4):787-798. [40] Hughes PA,Harrington AM,Castro J,et al.Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut.2013;62(10):1456-1465. [41] Long Y,Du L,Kim JJ,et al.MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice.Neurogastroenterol Motil.2018;30(9):e13348. [42] Ohman L,Simrén M.Pathogenesis of IBS:role of inflammation,immunity and neuroimmune interactions.Nat Rev Gastroenterol Hepatol.2010;7(3):163-173. [43] Peruhova M,Mihova A,Altankova I,Velikova T.Specific Immunoglobulin E and G to Common Food Antigens and Increased Serum Zonulin in IBS Patients:A Single-Center Bulgarian Study.Antibodies(Basel).2022;11(2):23.Published 2022 Mar 29. [44] Zamani M,Alizadeh-Tabari S,Zamani V.Systematic review with meta-analysis:the prevalence of anxiety and depression in patients with irritable bowel syndrome.Aliment Pharmacol Ther.2019 Jul;50(2):132-143. [45] Huang Y,Zheng E,Hu M,Yang X,Lan Q,Yu Y,Xu B.The impact of depression-mediated gut microbiota composition on Irritable Bowel Syndrome:A Mendelian study.J Affect Disord.2024 Sep 1;360:15-25.

点击下载PDF